ArticleScientific reports2016
Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Cathepsin D-driven IL2RG-JAK2 signal hijacking disrupts hepatic insulin action: mechanism-grounded proof that targeting cathepsin D prevents prediabetes.International journal of obesity (2005) · 2026Article
- Effects of an environmentally relevant mixture of organophosphate esters on the phenotype and function of HepG2 liver cells.Archives of toxicology · 2025Article
- Circulating Cathepsin D Exacerbates Injury-Induced Brain Damage by Promoting Neutrophil Infiltration Into the Brain.Journal of the American Heart Association · 2025Article
- Plasma cathepsin D as an early indicator of alcohol-related liver disease.JHEP reports : innovation in hepatology · 2024Article
- Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.JHEP reports : innovation in hepatology · 2024Review
- Targeted Proteomics Reveals Functional Targets for Early Diabetes Susceptibility in Young Adults.Circulation. Genomic and precision medicine · 2024Article
- Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease.Frontiers in nutrition · 2024Review
- Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies.Journal of clinical and translational hepatology · 2023Review
- Data-independent acquisition-based mass spectrometry(DIA-MS) for quantitative analysis of patients with chronic hepatitis B.Proteome science · 2023Article
- Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.World journal of hepatology · 2023Review
- All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma.Biomedicines · 2022Review
- Targeted Proteins Reveal Cathepsin D as a Novel Biomarker in Differentiating Hepatocellular Carcinoma from Cirrhosis and Other Liver CancersAsian Pacific journal of cancer prevention : APJCP · 2022Article
- Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice.Frontiers in immunology · 2021Article
- Review
- NAFLD Preclinical Models: More than a Handful, Less of a Concern?Biomedicines · 2020Review
- Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans.Diabetologia · 2020Article
- Oxidation-Specific Epitopes in Non-Alcoholic Fatty Liver Disease.Frontiers in endocrinology · 2020Review
- Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals.Frontiers in endocrinology · 2020Article
- Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.Gene expression · 2019Review
- Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic steatohepatitis (NASH) is characterized by liver lipid accumulation and inflammation. The mechanisms that trigger hepatic inflammation are poorly understood and subsequently, no specific non-invasive markers exist. We previously demonstrated a reduction in the plasma lysosomal enzyme, cathepsin D (CatD), in children with NASH compared to children without NASH. Recent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is distinct from children due to a different histological pattern in the liver. Yet, the link between plasma CatD to adult NASH was not examined. In the current manuscript, we investigated whether plasma CatD in adults correlates with NASH development and regression. Biopsies were histologically evaluated for inflammation and NAFLD in three complementary cohorts of adults (total n = 248). CatD and alanine aminotransferase (ALT) were measured in plasma. Opposite to our previous observations with childhood NASH, we observed increased levels of plasma CatD in patients with NASH compared to adults without hepatic inflammation. Furthermore, after surgical intervention, we found a reduction of plasma CatD compared to baseline. Our observations highlight a distinct pathophysiology between NASH in children and adults. The observation that plasma CatD correlated with NASH development and regression is promising for NASH diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.